share_log

SVB Leerink Maintains Outperform on Vincerx Pharma, Lowers Price Target to $5

Benzinga Real-time News ·  Aug 12, 2022 05:00

SVB Leerink analyst Jonathan Chang maintains Vincerx Pharma (NASDAQ:VINC) with a Outperform and lowers the price target from $6 to $5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment